Published: 23 October 2023
Author(s): Mario Bo, Stefano Fumagalli, Luca Degli Esposti, Valentina Perrone, Melania Dovizio, Daniela Poli, Rossella Marcucci, Paolo Verdecchia, Gianpaolo Reboldi, Gregory Y.H. Lip, Andrea Ungar, Alessandro Boccanelli, Carlo Fumagalli, Niccolò Marchionni, Italian Society of Geriatric Cardiology (SICGe)
Issue: March 2024
Section: Original article

Oral anticoagulant treatment (OAT) is strongly recommended for the prevention of ischemic stroke or systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and additive risk factors for cardio-embolic events. Evidence from randomized controlled trials (RCTs) [1] and observational studies consistently demonstrated a superior net clinical benefit of direct oral anticoagulants (DOACs) over vitamin K antagonists (VKAs) [2,3] although such a superiority may differ among DOACs [4,5].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.